Selected Posters and Abstracts
Tipranavir (Aptivus)
•Safety of tipranavir in heavily antiretroviral-experienced HIV-infected patients with and without chronic hepatitis B/C
P Garcia-Gasco and others.
•Efficacy of tipranavir oral solution co-administered with low dose ritonavir (TPV/r) is similar in all age groups of children and teenagers
C Giaquinto and others.
•Combined analysis of RESIST 96 week data: durability and efficacy of tipranavir/r in treatment experienced patients
B Gazzard and others.
•Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33
D Cooper and others.
•Lack of virologic response to the combination of tipranavir/ritonavir + enfuvirtide in treatment experienced HIV-infected persons with multi-drug resistant virus can be predicted by the presence of two or more of six mutations from five positions in protease
RD MacArthur and others.
•Genotypic resistance to tipranavir/ritonavir (TPV/r) in the Italian EAP BI 1182.16 study
A Saracino and others.
•Tipranavir genotypic inhibitory quotient predicts 24-week virological response to TPV-based salvage regimens
DG de Requena and others.
•Limited cross-resistance to tipranavir in patients previously treated with two or more protease inhibitors
V M Kohlbrenner and others.
•Better treatment response (TR) to tipranavir/r (TPV/r) compared to lopinavir/r (LPV/r) in patients with higher lopinavir (LPV) mutation scores
S Walmsley and others.

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva
Norvir
Prezista
Reyataz
Viracept

Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen

non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor
Sustiva
Viramune

Entry Inhibitors
 Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada